BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 28283584)

  • 21. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
    Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
    Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of molecular cytogenetic alterations in uterine leiomyosarcoma by array-based comparative genomic hybridization.
    Raish M; Khurshid M; Ansari MA; Chaturvedi PK; Bae SM; Kim JH; Park EK; Park DC; Ahn WS
    J Cancer Res Clin Oncol; 2012 Jul; 138(7):1173-86. PubMed ID: 22419440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma.
    Carlson JA; Caldeira Xavier JC; Tarasen A; Sheehan CE; Otto G; Miller VA; Stephens PJ; Elvin JA; Vergilio JA; Suh J; Gay LM; Ross JS
    Am J Dermatopathol; 2017 Jan; 39(1):1-13. PubMed ID: 28045747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functionality of the Tumor Suppressor
    Stope MB; Cernat V; Kaul A; Diesing K; Koensgen D; Burchardt M; Mustea A
    Anticancer Res; 2018 Mar; 38(3):1547-1550. PubMed ID: 29491084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular subtypes of uterine leiomyosarcoma and correlation with clinical outcome.
    Barlin JN; Zhou QC; Leitao MM; Bisogna M; Olvera N; Shih KK; Jacobsen A; Schultz N; Tap WD; Hensley ML; Schwartz GK; Boyd J; Qin LX; Levine DA
    Neoplasia; 2015 Feb; 17(2):183-9. PubMed ID: 25748237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive Genomic Profiling of Central Giant Cell Lesions Identifies Clinically Relevant Genomic Alterations.
    Bezak B; Lehrke H; Elvin J; Gay L; Schembri-Wismayer D; Viozzi C
    J Oral Maxillofac Surg; 2017 May; 75(5):955-961. PubMed ID: 27883876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway.
    Mao L; Dai J; Cao Y; Bai X; Sheng X; Chi Z; Cui C; Kong Y; Zhang Y; Wu L; Wang X; Tang B; Lian B; Yan X; Li S; Zhou L; Wei X; Li C; Qi Z; Si L; Guo J
    Eur J Cancer; 2021 May; 148():297-306. PubMed ID: 33770575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.
    Ross JS; Badve S; Wang K; Sheehan CE; Boguniewicz AB; Otto GA; Yelensky R; Lipson D; Ali S; Morosini D; Chliemlecki J; Elvin JA; Miller VA; Stephens PJ
    Arch Pathol Lab Med; 2015 May; 139(5):642-9. PubMed ID: 25927147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm.
    Arend RC; Toboni MD; Montgomery AM; Burger RA; Olawaiye AB; Monk BJ; Herzog TJ
    Oncologist; 2018 Dec; 23(12):1533-1545. PubMed ID: 30139839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.
    Pal SK; Ali SM; Yakirevich E; Geynisman DM; Karam JA; Elvin JA; Frampton GM; Huang X; Lin DI; Rosenzweig M; Lipson D; Stephens PJ; Ross JS; Miller VA; Agarwal N; Shuch B; Choueiri TK; Chung JH
    Eur Urol; 2018 Jan; 73(1):71-78. PubMed ID: 28592388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma.
    Dermawan JK; Chiang S; Singer S; Jadeja B; Hensley ML; Tap WD; Movva S; Maki RG; Antonescu CR
    Clin Cancer Res; 2024 May; 30(10):2260-2271. PubMed ID: 38488807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of CDKN2A Promoter Methylation Coincides With the Epigenetic Transdifferentiation of Uterine Myosarcomatous Cells.
    Roncati L; Barbolini G; Sartori G; Siopis E; Pusiol T; Maiorana A
    Int J Gynecol Pathol; 2016 Jul; 35(4):309-15. PubMed ID: 27276112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting Class I Histone Deacetylases in Human Uterine Leiomyosarcoma.
    Yang Q; Falahati A; Khosh A; Mohammed H; Kang W; Corachán A; Bariani MV; Boyer TG; Al-Hendy A
    Cells; 2022 Nov; 11(23):. PubMed ID: 36497061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abnormal p53 and p16 staining patterns distinguish uterine leiomyosarcoma from inflammatory myofibroblastic tumour.
    Schaefer IM; Hornick JL; Sholl LM; Quade BJ; Nucci MR; Parra-Herran C
    Histopathology; 2017 Jun; 70(7):1138-1146. PubMed ID: 28130839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy.
    Rose TL; Chism DD; Alva AS; Deal AM; Maygarden SJ; Whang YE; Kardos J; Drier A; Basch E; Godley PA; Dunn MW; Kim WY; Milowsky MI
    Br J Cancer; 2018 Oct; 119(7):801-807. PubMed ID: 30293995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular differential analysis of uterine leiomyomas and leiomyosarcomas through weighted gene network and pathway tracing approaches.
    Sahly NN; Banaganapalli B; Sahly AN; Aligiraigri AH; Nasser KK; Shinawi T; Mohammed A; Alamri AS; Bondagji N; Elango R; Shaik NA
    Syst Biol Reprod Med; 2021 Jun; 67(3):209-220. PubMed ID: 33685300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
    Ross JS; Ali SM; Wang K; Khaira D; Palma NA; Chmielecki J; Palmer GA; Morosini D; Elvin JA; Fernandez SV; Miller VA; Stephens PJ; Cristofanilli M
    Breast Cancer Res Treat; 2015 Nov; 154(1):155-62. PubMed ID: 26458824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.
    Wang K; Johnson A; Ali SM; Klempner SJ; Bekaii-Saab T; Vacirca JL; Khaira D; Yelensky R; Chmielecki J; Elvin JA; Lipson D; Miller VA; Stephens PJ; Ross JS
    Oncologist; 2015 Oct; 20(10):1132-9. PubMed ID: 26336083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
    Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
    Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
    Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
    Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.